Challenge
A Fortune 500 pharmaceutical company standardized its web ecosystem onto Sitecore as part of a broader effort to improve platform stability, governance, scalability, and long-term operational consistency across a large portfolio of digital properties. The initiative reduced platform fragmentation and created a more unified technology environment across the organization.
However, the standardized delivery model — combined with a smaller pool of approved premium development vendors — created cost challenges for smaller pharmaceutical brands that did not have the same marketing budgets as larger flagship products. In many cases, even relatively basic website updates or redesigns became difficult to justify financially under the approved enterprise delivery model.
Insight
The regulatory realities of the pharmaceutical industry changed how much value some brands could practically gain from a full enterprise CMS implementation. Extensive legal, compliance, and FDA review processes limited the operational need for many advanced CMS capabilities, particularly for lower-volume brand sites with relatively static content requirements.
Rather than applying the same enterprise delivery model universally, a more practical approach was to introduce a right-sized web delivery strategy that still aligned with governance expectations while significantly reducing operational and financial overhead for smaller brands.
Solution
Worked closely with marketing, technology, and business stakeholders to identify situations where a lower-cost alternative to the standard Sitecore implementation model made operational and financial sense. Helped define, secure approval for, and implement a lighter-weight static website approach for smaller brands using an approved lower-cost delivery partner.
The engagement supported both the strategic alignment and hands-on execution of these projects, including vendor coordination, delivery oversight, stakeholder communication, implementation management, and governance alignment to ensure sites launched within budget while still meeting organizational standards and compliance expectations.
Results
Smaller pharmaceutical brands were able to complete website updates and redesigns that otherwise may have been delayed or deprioritized due to enterprise implementation costs.
The alternative delivery model reduced vendor development spend across participating brands by hundreds of thousands of dollars while still maintaining alignment with broader governance, compliance, and technology objectives. Reduced implementation costs also allowed marketing teams to redirect budget toward additional campaigns, business initiatives, and higher-priority brand activities rather than consuming disproportionate spend on basic website maintenance and rebuild efforts.